Anti-tuberculosis treatment strategies and drug development: challenges and priorities.

ABSTRACT: Despite two decades of intensified research to understand and cure tuberculosis disease, biological uncertainties remain and hamper progress. However, owing to collaborative initiatives including academia, the pharmaceutical industry and non-for-profit organizations, the drug candidate pipeline is promising. This exceptional success comes with the inherent challenge of prioritizing multidrug regimens for clinical trials and revamping trial designs to accelerate regimen development and capitalize on drug discovery breakthroughs. Most wanted are markers of progression from latent infection to active pulmonary disease, markers of drug response and predictors of relapse, in vitro tools to uncover synergies that translate clinically and animal models to reliably assess the treatment shortening

SUBMITTER: Dartois VA 

PROVIDER: S-EPMC9045034 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature